# EDGAR Filing Document

**Accession Number:** 0001801917
**File Stem:** 0001140361-25-037740
**Filing Date:** 2025-10
**Character Count:** 8893
**Document Hash:** 97d0d1e9ede7aee134d0f8c59c958466
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-037740.hdr.sgml**: 20251008

**ACCESSION NUMBER**: 0001140361-25-037740

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251006

**FILED AS OF DATE**: 20251008

**DATE AS OF CHANGE**: 20251008

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Venker Eric
- **CENTRAL INDEX KEY:** 0001801917

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40782
- **FILM NUMBER:** 251383469

**MAIL ADDRESS:**
- **STREET 1:** C/O ROIVANT SCIENCES, INC.
- **STREET 2:** 320 WEST 37TH STREET, 6TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Roivant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001635088
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981173944
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0331

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB
- **BUSINESS PHONE:** 441-295-5950

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Venker Eric<br><sub>(Last) (First) (Middle)</sub><br>C/O ROIVANT SCIENCES LTD.<br>7TH FLOOR, 50 BROADWAY<br><sub>(Street)</sub><br>LONDON, X0 SW1H 0DB<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & Immunovant CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Roivant Sciences Ltd. [ ROIV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2025-10-06 |  | M |  | 127355 | A | $15.85 | 1632314 | D |  |
| Common Shares | 2025-10-06 |  | M |  | 24900 | A | $7.45 | 1657214 | D |  |
| Common Shares | 2025-10-06 |  | M |  | 19141 | A | $3.85 | 1676355 | D |  |
| Common Shares | 2025-10-06 |  | S |  | 171396 | D | 16.34<sup>(1)</sup> | 1504959 | D |  |
| Common Shares | 2025-10-07 |  | M |  | 67171 | A | $15.85 | 1572130 | D |  |
| Common Shares | 2025-10-07 |  | M |  | 107131 | A | $7.45 | 1679261 | D |  |
| Common Shares | 2025-10-07 |  | M |  | 180859 | A | $3.85 | 1860120 | D |  |
| Common Shares | 2025-10-07 |  | S |  | 355161 | D | 16.15<sup>(1)</sup> | 1504959 | D |  |
| Common Shares | 2025-10-08 |  | M |  | 10307 | A | $15.85 | 1515266 | D |  |
| Common Shares | 2025-10-08 |  | M |  | 128295 | A | $7.45 | 1643561 | D |  |
| Common Shares | 2025-10-08 |  | S |  | 138602 | D | 16.2<sup>(1)</sup> | 1504959 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $15.85 | 2025-10-06 |  | M |  |  | 127355 | <sup>(2)</sup> | 2026-03-31 | Common Stock | 127355 | $0 | 1054528 | D |  |
| Stock Option (Right to Buy) | $7.45 | 2025-10-06 |  | M |  |  | 24900 | <sup>(3)</sup> | 2027-11-20 | Common Stock | 24900 | $0 | 235426 | D |  |
| Stock Option (Right to Buy) | $3.85 | 2025-10-06 |  | M |  |  | 19141 | <sup>(4)</sup> | 2032-04-19 | Common Stock | 19141 | $0 | 6457382 | D |  |
| Stock Option (Right to Buy) | $15.85 | 2025-10-07 |  | M |  |  | 67171 | <sup>(2)</sup> | 2026-03-31 | Common Stock | 67171 | $0 | 987357 | D |  |
| Stock Option (Right to Buy) | $7.45 | 2025-10-07 |  | M |  |  | 107131 | <sup>(3)</sup> | 2027-11-20 | Common Stock | 107131 | $0 | 128295 | D |  |
| Stock Option (Right to Buy) | $3.85 | 2025-10-07 |  | M |  |  | 180859 | <sup>(4)</sup> | 2032-04-19 | Common Stock | 180859 | $0 | 6276523 | D |  |
| Stock Option (Right to Buy) | $15.85 | 2025-10-08 |  | M |  |  | 10307 | <sup>(2)</sup> | 2026-03-31 | Common Stock | 10307 | $0 | 977050 | D |  |
| Stock Option (Right to Buy) | $7.45 | 2025-10-08 |  | M |  |  | 128295 | <sup>(3)</sup> | 2027-11-20 | Common Stock | 128295 | $0 | 0 | D |  |

---

### Footnotes:

(1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

(2) Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

(3) Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.

(4) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

**Signature:** By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker  
**Date:** 2025-10-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**